GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhongzhi Pharmaceutical Holdings Ltd (HKSE:03737) » Definitions » Beneish M-Score

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Beneish M-Score : -2.15 (As of Apr. 11, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Zhongzhi Pharmaceutical Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.15 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zhongzhi Pharmaceutical Holdings's Beneish M-Score or its related term are showing as below:

HKSE:03737' s Beneish M-Score Range Over the Past 10 Years
Min: -2.9   Med: -2.33   Max: -1.74
Current: -2.15

During the past 11 years, the highest Beneish M-Score of Zhongzhi Pharmaceutical Holdings was -1.74. The lowest was -2.90. And the median was -2.33.


Zhongzhi Pharmaceutical Holdings Beneish M-Score Historical Data

The historical data trend for Zhongzhi Pharmaceutical Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongzhi Pharmaceutical Holdings Beneish M-Score Chart

Zhongzhi Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.99 -2.66 -2.90 -2.15 -

Zhongzhi Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.90 - -2.15 - -

Competitive Comparison of Zhongzhi Pharmaceutical Holdings's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Zhongzhi Pharmaceutical Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhongzhi Pharmaceutical Holdings's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhongzhi Pharmaceutical Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zhongzhi Pharmaceutical Holdings's Beneish M-Score falls into.


;
;

Zhongzhi Pharmaceutical Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zhongzhi Pharmaceutical Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9519+0.528 * 0.9882+0.404 * 1.208+0.892 * 1.0996+0.115 * 1.0953
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9689+4.679 * 0.03418-0.327 * 0.8966
=-2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was HK$387 Mil.
Revenue was HK$2,242 Mil.
Gross Profit was HK$1,332 Mil.
Total Current Assets was HK$956 Mil.
Total Assets was HK$1,961 Mil.
Property, Plant and Equipment(Net PPE) was HK$739 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$112 Mil.
Selling, General, & Admin. Expense(SGA) was HK$1,088 Mil.
Total Current Liabilities was HK$666 Mil.
Long-Term Debt & Capital Lease Obligation was HK$109 Mil.
Net Income was HK$178 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$111 Mil.
Total Receivables was HK$370 Mil.
Revenue was HK$2,039 Mil.
Gross Profit was HK$1,197 Mil.
Total Current Assets was HK$1,218 Mil.
Total Assets was HK$2,094 Mil.
Property, Plant and Equipment(Net PPE) was HK$641 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$108 Mil.
Selling, General, & Admin. Expense(SGA) was HK$1,021 Mil.
Total Current Liabilities was HK$817 Mil.
Long-Term Debt & Capital Lease Obligation was HK$106 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(386.809 / 2242.041) / (369.566 / 2039.048)
=0.172525 / 0.181244
=0.9519

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1197.448 / 2039.048) / (1332.379 / 2242.041)
=0.587258 / 0.594271
=0.9882

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (956.095 + 739.388) / 1960.746) / (1 - (1218.246 + 641.356) / 2094.127)
=0.135287 / 0.111992
=1.208

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2242.041 / 2039.048
=1.0996

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(107.633 / (107.633 + 641.356)) / (111.652 / (111.652 + 739.388))
=0.143704 / 0.131195
=1.0953

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1088.099 / 2242.041) / (1021.31 / 2039.048)
=0.485316 / 0.500876
=0.9689

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((108.585 + 665.683) / 1960.746) / ((105.665 + 816.599) / 2094.127)
=0.394884 / 0.440405
=0.8966

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(178.04 - 0 - 111.022) / 1960.746
=0.03418

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zhongzhi Pharmaceutical Holdings has a M-score of -2.15 suggests that the company is unlikely to be a manipulator.


Zhongzhi Pharmaceutical Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Zhongzhi Pharmaceutical Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhongzhi Pharmaceutical Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Kangtai Road South, Torch Development Zone, Guangdong Province, Zhongshan, CHN
Zhongzhi Pharmaceutical Holdings Ltd is engaged in the business of manufacturing and selling pharmaceutical products. The group's operations can be divided into three segments, namely Pharmaceutical manufacturing, Operation of chain pharmacies, and Operation of online pharmacies in Zhongshan in the Guangdong province, the PRC. In the Pharmaceutical manufacturing segment, the company is engaged in the research and development, manufacturing and sale of Chinese patent medicines. In the Operation of chain pharmacies segment, the firm operates chain pharmacies in Zhongshan under the brand Zeus for the sale of pharmaceutical products. The Operation of online pharmacies segment sells medicines online. It derives a majority of its revenue from the PRC.
Executives
Jiang Li Xia 2202 Interest of your spouse
Lai Zhi Tian 2201 Interest of corporation controlled by you
Crystal Talent Investment Group Limited 2101 Beneficial owner
Cheng Jin Le 2201 Interest of corporation controlled by you
Advance Keypath Global Investment Limited 2101 Beneficial owner
Novich Positioning Investment (cayman) Limited 2201 Interest of corporation controlled by you
Novich Positioning Investment Limited Partnership 2101 Beneficial owner

Zhongzhi Pharmaceutical Holdings Headlines

No Headlines